Trevi Therapeutics | 8-K: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Trevi Therapeutics | 10-K: Annual report
Trevi Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Trevi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Simon Farrell
Trevi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Galletta Christopher
Trevi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Clark David J
Trevi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer GOOD JENNIFER L
Trevi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer SCIASCIA THOMAS
Trevi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Delfini Lisa
Trevi Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Venrock Healthcare Capital Partners II, L.P.(9.99%),VHCP Co-Investment Holdings II, LLC(9.99%), etc.
Trevi Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Fairmount Funds Management LLC(0.0%),Peter Harwin(0.0%), etc.
Trevi Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Viking Global Investors LP(9.99%),Viking Global Opportunities Parent GP LLC(9.99%), etc.
Trevi Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(8.90%),David Rosen(8.90%)
Trevi Therapeutics: Q3 2023 Earnings Report
Trevi Therapeutics | 8-K: Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
Trevi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Delfini Lisa
Trevi Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Delfini Lisa
Trevi Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Trevi Therapeutics | EFFECT: Others
Trevi Therapeutics | CORRESP: CORRESP
No Data